{"protocolSection": {"identificationModule": {"nctId": "NCT03357731", "orgStudyIdInfo": {"id": "CV013-020"}, "secondaryIdInfos": [{"id": "2016-003586-26", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function"}, "statusModule": {"statusVerifiedDate": "2020-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2017-11-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-05-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-05-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2017-10-31", "studyFirstSubmitQcDate": "2017-11-29", "studyFirstPostDateStruct": {"date": "2017-11-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-05-06", "resultsFirstSubmitQcDate": "2020-07-24", "resultsFirstPostDateStruct": {"date": "2020-07-27", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-07-24", "lastUpdatePostDateStruct": {"date": "2020-07-27", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction."}, "conditionsModule": {"conditions": ["Heart Failure", "Cardiac Failure", "Reduced Ventricular Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 49, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo/BMS-986231/NTG", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}, {"label": "Placebo/NTG/BMS-986231", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}, {"label": "NTG/Placebo/BMS-986231", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}, {"label": "NTG/BMS-986231/Placebo", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}, {"label": "BMS-986231/Placebo/NTG", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}, {"label": "BMS-986231/NTG/Placebo", "type": "EXPERIMENTAL", "description": "administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods", "interventionNames": ["Drug: HNO Donor", "Drug: Nitroglycerin (NTG)", "Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "HNO Donor", "description": "Infusion", "armGroupLabels": ["BMS-986231/NTG/Placebo", "BMS-986231/Placebo/NTG", "NTG/BMS-986231/Placebo", "NTG/Placebo/BMS-986231", "Placebo/BMS-986231/NTG", "Placebo/NTG/BMS-986231"], "otherNames": ["BMS-986231"]}, {"type": "DRUG", "name": "Nitroglycerin (NTG)", "description": "Infusion", "armGroupLabels": ["BMS-986231/NTG/Placebo", "BMS-986231/Placebo/NTG", "NTG/BMS-986231/Placebo", "NTG/Placebo/BMS-986231", "Placebo/BMS-986231/NTG", "Placebo/NTG/BMS-986231"]}, {"type": "OTHER", "name": "Placebo", "description": "Infusion", "armGroupLabels": ["BMS-986231/NTG/Placebo", "BMS-986231/Placebo/NTG", "NTG/BMS-986231/Placebo", "NTG/Placebo/BMS-986231", "Placebo/BMS-986231/NTG", "Placebo/NTG/BMS-986231"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo", "description": "The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.", "timeFrame": "at the end of the 5-hour infusion"}], "secondaryOutcomes": [{"measure": "Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG", "description": "The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.", "timeFrame": "at the end of the 5-hour infusion"}, {"measure": "Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nLV ejection fraction", "timeFrame": "at the end of the 5-hour infusion"}, {"measure": "Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nMean LV power index", "timeFrame": "at the end of the 5-hour infusion"}, {"measure": "Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nDiastolic function", "timeFrame": "at the end of the 5-hour infusion"}, {"measure": "Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nDiastolic function", "timeFrame": "at the end of the 5-hour infusion"}, {"measure": "Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nLV global longitudinal strain", "timeFrame": "at the end of the 5-hour infusion"}]}, "eligibilityModule": {"eligibilityCriteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less)\n* Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and \u03b2 blockers as tolerated, with no dose changes of these medications in the past 2 weeks\n* Have screening values of NT pro-BNP \u2265 125 pg/mL (15 pmol/L) or BNP \u2265 35 pg/mL (10 pmol/L)\n\nExclusion Criteria:\n\n* Systolic blood pressure (SBP) \\< 110 mm Hg at screening or pre-randomization\n* Heart rate \\< 50 beats per minute (bpm) or \\> 90 bpm at screening or pre-randomization\n* Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter\n* Estimated glomerular filtration rate (eGFR) \\< 15 ml/min/1.73 m2\n* Ventricular assist device or prior heart transplant\n* Prior solid organ transplant\n* Body weight \\< 45 kg or \u2265 140 kg\n* Low quality echocardiographic visualization windows and image acquisition\n* Permanent paced rhythm (VVI, DDD or BiV pacing)\n\nOther protocol defined inclusion/exclusion criteria could apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Orange County Research Center", "city": "Tustin", "state": "California", "zip": "92780", "country": "United States", "geoPoint": {"lat": 33.74585, "lon": -117.82617}}, {"facility": "Northwestern Medicine", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Indiana University School of Medicine-Indianapolis", "city": "Indianapolis", "state": "Indiana", "zip": "46202-1218", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Brigham and Womens Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Duke Advanced Heart and Lung Failure Clinic", "city": "Durham", "state": "North Carolina", "zip": "27710", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Inova Heart and Vascular Institute", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Local Institution", "city": "Nagoya", "state": "Aichi", "zip": "466-8560", "country": "Japan", "geoPoint": {"lat": 35.18147, "lon": 136.90641}}, {"facility": "Local Institution", "city": "Kawasaki", "state": "Kanagawa", "zip": "211-8533", "country": "Japan", "geoPoint": {"lat": 35.52056, "lon": 139.71722}}, {"facility": "Local Institution", "city": "Suita-shi", "state": "Osaka", "zip": "5650871", "country": "Japan", "geoPoint": {"lat": 34.76143, "lon": 135.51567}}, {"facility": "Local Institution", "city": "Groiningen", "zip": "9713GZ", "country": "Netherlands"}, {"facility": "Local Institution", "city": "Edinburgh", "zip": "EH16 4SA", "country": "United Kingdom", "geoPoint": {"lat": 55.95206, "lon": -3.19648}}, {"facility": "Local Institution", "city": "Glasgow", "zip": "G4 0SF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Local Institution", "city": "Glasgow", "zip": "G429LF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Local Institution", "city": "Glasgow", "zip": "G51 4TF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Local Institution", "city": "Harrow", "zip": "HA1 3UJ", "country": "United Kingdom", "geoPoint": {"lat": 51.57142, "lon": -0.33371}}, {"facility": "Local Institution", "city": "London", "zip": "SE1 1YR", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Local Institution", "city": "London", "zip": "sw17 0re", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Local Institution", "city": "London", "zip": "SW3 6NP", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "31168885", "type": "DERIVED", "citation": "Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6."}], "seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "https://www.bmsstudyconnect.com/s/US/English/USenHome"}, {"label": "FDA Safety Alerts and Recalls", "url": "https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "49 participants assigned to treatment and 45 treated. Reasons not treated: 2 re-randomized; 1 randomized in error, screen failure; 1 no longer met study criteria.\n\nNote: Study designed for all participants to enter all 3 arms (reassignment of arms occurs every period change).", "groups": [{"id": "FG000", "title": "Sequence 1", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: PBO-drug-NTG"}, {"id": "FG001", "title": "Sequence 2", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: PBO-NTG-drug"}, {"id": "FG002", "title": "Sequence 3", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: NTG-PBO-drug"}, {"id": "FG003", "title": "Sequence 4", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: NTG-drug-PBO"}, {"id": "FG004", "title": "Sequence 5", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: drug-PBO-NTG"}, {"id": "FG005", "title": "Sequence 6", "description": "Participants crossed-over from one therapy to the next following Day 1 treatment and a minimum 5-day washout period.\n\n3 treatments were given via 1 of 6 different order sequences across 3 total treatment periods, 1 treatment per period. Treatments were as follows: Placebo (PBO) BMS-986231 (drug) Nitroglycerin (NTG)\n\nSequence of treatment for this group is as follows: drug-NTG-PBO"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "started = received Period 1 assigned treatment", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "8"}, {"groupId": "FG005", "numSubjects": "8"}]}, {"type": "Completed Period 1 (P1)", "achievements": [{"groupId": "FG000", "comment": "1 withdrew post-P1 completion/prior to P2 therapy due to acute cholecystitis, but returned for P2/P3", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "comment": "1 discontinued P1 due to acute bradycardia and hypotension", "numSubjects": "6"}, {"groupId": "FG004", "comment": "1 discontinued P1 due to hypotension but resumed P2/P3", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "8"}]}, {"type": "Completed Period 2 (P2)", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "7"}, {"groupId": "FG003", "comment": "1 completed P1, did not proceed to P2/P3 (lost to follow-up);\n\n1 discontinued P2 due to hypotension", "numSubjects": "4"}, {"groupId": "FG004", "comment": "1 only completed P1, did not continue to P2/P3 (withdrew consent due to personal reasons)", "numSubjects": "7"}, {"groupId": "FG005", "comment": "1 discontinued P2 due to an Adverse Event (AE)", "numSubjects": "7"}]}, {"type": "COMPLETED", "comment": "completed = finished Period 3 (P3) assigned treatment", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "comment": "1 discontinuation due to hypotension", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "4"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrew consent due to personal reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Acute bradycardia and hypotension", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Hypotension", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Overall Participants", "description": "Inclusive of all treatments, all periods. Note: Participants crossed-over from either placebo, drug or NTG arm to the next (in various sequence) following Day 1 treatment and a minimum 5-day washout period, per arm."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "45"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "20"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "25"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.7", "spread": "12.35"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "8"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "37"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "43"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "40"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo", "description": "The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "29.545", "spread": "7.0243"}, {"groupId": "OG001", "value": "28.721", "spread": "9.0174"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.027", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-2.150", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-4.0432", "ciUpperLimit": "-0.2570", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.9242", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG", "description": "The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/m^2", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "37"}, {"groupId": "OG002", "value": "41"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "28.721", "spread": "9.0174"}, {"groupId": "OG002", "value": "27.811", "spread": "7.9712"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.846", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "0.193", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.8176", "ciUpperLimit": "2.2042", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.9832", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nLV ejection fraction", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of blood pumped from the LV", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31.9", "spread": "7.15"}, {"groupId": "OG001", "value": "32.8", "spread": "8.24"}, {"groupId": "OG002", "value": "33.5", "spread": "7.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.177", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.62", "ciUpperLimit": "3.19", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.93", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.839", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.08", "ciUpperLimit": "0.88", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.48", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nMean LV power index", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "watts per square meter (W/m^2)", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "39"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.4122", "spread": "0.14404"}, {"groupId": "OG001", "value": "0.3427", "spread": "0.10463"}, {"groupId": "OG002", "value": "0.3568", "spread": "0.09184"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.007", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.0977", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.16634", "ciUpperLimit": "-0.02915", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03308", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.103", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.0371", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.08243", "ciUpperLimit": "0.00814", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.02194", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nDiastolic function", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "E/A ratio", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "36"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "36"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.80", "spread": "0.278"}, {"groupId": "OG001", "value": "0.73", "spread": "0.270"}, {"groupId": "OG002", "value": "0.71", "spread": "0.310"}]}]}, {"title": "E/e' ratio", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "37"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.42", "spread": "4.102"}, {"groupId": "OG001", "value": "7.00", "spread": "2.464"}, {"groupId": "OG002", "value": "7.81", "spread": "2.652"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "E/A ratio", "nonInferiorityType": "SUPERIORITY", "pValue": "0.003", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.13", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.205", "ciUpperLimit": "-0.051", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.037", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "groupDescription": "E/A ratio", "nonInferiorityType": "SUPERIORITY", "pValue": "0.904", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.051", "ciUpperLimit": "0.057", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.026", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG000", "OG001"], "groupDescription": "E/e' ratio", "nonInferiorityType": "SUPERIORITY", "pValue": "0.006", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-1.66", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.763", "ciUpperLimit": "-0.549", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.527", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "groupDescription": "E/e' ratio", "nonInferiorityType": "SUPERIORITY", "pValue": "0.503", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.27", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.085", "ciUpperLimit": "0.550", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.392", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nDiastolic function", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm/sec", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.18", "spread": "2.467"}, {"groupId": "OG001", "value": "8.07", "spread": "2.333"}, {"groupId": "OG002", "value": "7.18", "spread": "2.143"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "annular e' velocity", "nonInferiorityType": "SUPERIORITY", "pValue": "0.994", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.827", "ciUpperLimit": "0.820", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.398", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "groupDescription": "annular e' velocity", "nonInferiorityType": "SUPERIORITY", "pValue": "0.073", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "0.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.049", "ciUpperLimit": "1.013", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.258", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}, {"type": "SECONDARY", "title": "Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG", "description": "Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG:\n\nLV global longitudinal strain", "populationDescription": "Intent to Treat (ITT) population: All randomized participants who started study drug infusion in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of blood pumped from the LV", "timeFrame": "at the end of the 5-hour infusion", "groups": [{"id": "OG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}, {"id": "OG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "38"}, {"groupId": "OG001", "value": "36"}, {"groupId": "OG002", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.98", "spread": "2.860"}, {"groupId": "OG001", "value": "-11.94", "spread": "3.458"}, {"groupId": "OG002", "value": "-11.36", "spread": "3.067"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.705", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "0.15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.670", "ciUpperLimit": "0.976", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.400", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.105", "statisticalMethod": "Kenward-Roger degree of freedom", "statisticalComment": "Kenward-Roger degree of freedom is used to adjust the standard error of treatment effect", "paramType": "Mean Difference (Net)", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.504", "ciUpperLimit": "0.151", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.404", "estimateComment": "The modelled mean difference uses treatment sequence and difference of baselines as a covariates of the treatment effect."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose to 30 days post last dose (approximately 3 months)", "eventGroups": [{"id": "EG000", "title": "Placebo (PBO)", "description": "Placebo-matching treatment. Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO", "deathsNumAffected": 0, "deathsNumAtRisk": 40, "seriousNumAffected": 1, "seriousNumAtRisk": 40, "otherNumAffected": 2, "otherNumAtRisk": 40}, {"id": "EG001", "title": "BMS-986231", "description": "BMS-986231: 3 \u03bcg/kg/min for 10 min, followed by 6 \u03bcg/kg/min for 10 min, followed by 12 \u03bcg/kg/min for the rest of the 5-hour infusion.\n\nNote: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO", "deathsNumAffected": 0, "deathsNumAtRisk": 42, "seriousNumAffected": 0, "seriousNumAtRisk": 42, "otherNumAffected": 12, "otherNumAtRisk": 42}, {"id": "EG002", "title": "Nitroglycerin (NTG)", "description": "NTG: 20 \u03bcg/min for 10 min, followed by 40 \u03bcg/min for 10 min, followed by 80 \u03bcg/min for the rest of the 5-hour infusion Note: Participants crossed-over from one arm to the next following Day 1 treatment and a minimum 5-day washout period, per arm.\n\nTreatment was given via 1 of 6 different order sequences across 3 total treatment periods. Participant therapy sequence assignment varies as follows:\n\nPBO-drug-NTG, PBO-NTG-drug, NTG-PBO-drug, NTG-drug-PBO, drug-PBO-NTG, drug-NTG-PBO", "deathsNumAffected": 0, "deathsNumAtRisk": 44, "seriousNumAffected": 1, "seriousNumAtRisk": 44, "otherNumAffected": 10, "otherNumAtRisk": 44}], "seriousEvents": [{"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 44}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 44}]}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 44}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 22.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 40}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 42}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 44}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com", "phone": "Please email:"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-12-06", "uploadDate": "2020-05-06T14:44", "filename": "SAP_000.pdf", "size": 1097000}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-01-24", "uploadDate": "2020-05-06T14:56", "filename": "Prot_001.pdf", "size": 830739}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2020-05-29", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000005996", "term": "Nitroglycerin"}], "ancestors": [{"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M9102", "name": "Nitroglycerin", "asFound": "RSV", "relevance": "HIGH"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}